VOR — Vor Biopharma Cashflow Statement
0.000.00%
- $749.43m
- $294.23m
Annual cashflow statement for Vor Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -68.9 | -92.1 | -118 | -117 | -696 |
| Depreciation | |||||
| Non-Cash Items | 7.33 | 17.1 | 13.4 | 13.7 | 540 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.01 | -12.7 | 0.65 | 0.005 | 10.2 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -69.1 | -85.1 | -100 | -99.7 | -143 |
| Capital Expenditures | -3.89 | -8.46 | -1.07 | -0.229 | -0.941 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -87.8 | -85.6 | 72.1 | 97.1 | -47.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -91.7 | -94.1 | 71 | 96.9 | -48.8 |
| Financing Cash Flow Items | -2.21 | 0 | -0.717 | -2.33 | -1.32 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 233 | 117 | 2.94 | 53.4 | 504 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 72.1 | -62.1 | -26.3 | 50.6 | 312 |